Title: In vitro susceptibility of clinical Clostridioides difficile isolates in Israel to metronidazole,
vancomycin, fidaxomicin, ridinilazole and ibezapolstat
Version: 3 Date: 25 Feb 2025
Reviewer's report:
Dear authors, thank you for the opportunity to read the results of your research. CDI still
represents a significant healthcare problem, primarily due to the high recurrence rate, resulting
from unsuccessful treatment.
Therefore, research on the application of new therapeutic options is extremely welcome.
In my opinion, certain clarifications and adjustments to the manuscript are needed before
publication.
Please, read the entire manuscript carefully; in several places IBEZAPOLSTAT is misspelled
as IBEZPOLSTAT (e.g. line 33).
Line 19: please write the full name, because the bacterium is mentioned here for the first time
Furthermore, replace "E-test" (which is a trademark of the manufacturer Biomerieux), please
use the name "gradient strip test" (e.g. line 38).
Line 50: delete "onset"
Line 109: add references for these definitions
Methods
Please change places in the manuscript by first writing "Bacterial isolation and identification",
and then "MLST"
Figures and Tables
Please write the title before each figure, and below the figure a "legend" with explanations of
the content of the figure.
Figure 1: The icons with colors are too small, please enlarge them for easier understanding.
Discussion
The discussion is too broad, the authors are re-presenting all the results. Please, significantly
shorten the discussion by comparing your most significant results with the results of other
authors.
Title: In vitro susceptibility of clinical Clostridioides difficile isolates in Israel to metronidazole,
vancomycin, fidaxomicin, ridinilazole and ibezapolstat
Version: 3 Date: 25 Feb 2025
Reviewer's report:
Dear authors, thank you for the opportunity to read the results of your research. CDI still
represents a significant healthcare problem, primarily due to the high recurrence rate, resulting
from unsuccessful treatment.
Therefore, research on the application of new therapeutic options is extremely welcome.
In my opinion, certain clarifications and adjustments to the manuscript are needed before
publication.
Please, read the entire manuscript carefully; in several places IBEZAPOLSTAT is misspelled
as IBEZPOLSTAT (e.g. line 33).
Line 19: please write the full name, because the bacterium is mentioned here for the first time
Furthermore, replace "E-test" (which is a trademark of the manufacturer Biomerieux), please
use the name "gradient strip test" (e.g. line 38).
Line 50: delete "onset"
Line 109: add references for these definitions
Methods
Please change places in the manuscript by first writing "Bacterial isolation and identification",
and then "MLST"
Figures and Tables
Please write the title before each figure, and below the figure a "legend" with explanations of
the content of the figure.
Figure 1: The icons with colors are too small, please enlarge them for easier understanding.
Discussion
The discussion is too broad, the authors are re-presenting all the results. Please, significantly
shorten the discussion by comparing your most significant results with the results of other
authors.
Please review this paper.
user
Title: In vitro susceptibility of clinical Clostridioides difficile isolates in Israel to metronidazole,
vancomycin, fidaxomicin, ridinilazole and ibezapolstat
Version: 3 Date: 25 Feb 2025
Reviewer's report:
Dear authors, thank you for the opportunity to read the results of your research. CDI still
represents a significant healthcare problem, primarily due to the high recurrence rate, resulting
from unsuccessful treatment.
Therefore, research on the application of new therapeutic options is extremely welcome.
In my opinion, certain clarifications and adjustments to the manuscript are needed before
publication.
Please, read the entire manuscript carefully; in several places IBEZAPOLSTAT is misspelled
as IBEZPOLSTAT (e.g. line 33).
Line 19: please write the full name, because the bacterium is mentioned here for the first time
Furthermore, replace "E-test" (which is a trademark of the manufacturer Biomerieux), please
use the name "gradient strip test" (e.g. line 38).
Line 50: delete "onset"
Line 109: add references for these definitions
Methods
Please change places in the manuscript by first writing "Bacterial isolation and identification",
and then "MLST"
Figures and Tables
Please write the title before each figure, and below the figure a "legend" with explanations of
the content of the figure.
Figure 1: The icons with colors are too small, please enlarge them for easier understanding.
Discussion
The discussion is too broad, the authors are re-presenting all the results. Please, significantly
shorten the discussion by comparing your most significant results with the results of other
authors.
assistant